Tag Archives: Clinical Guidance

Drug Regulators Publish Draft Clinical Guidelines for Cancer Vaccines

Drug Regulators, FDA CBER, Publish Draft Clinical Guidance for Cancer Vaccines.

full text here

This guidance provides sponsors who wish to submit an Investigational New Drug application (IND) for a therapeutic cancer vaccine, recommendations on critical clinical considerations for investigational studies of these products. This guidance will discuss considerations common to phase 1 and phase 2 clinical trials (which collectively may be referred to as “early phase clinical trials”) and phase 3 clinical trials (which may be referred to as “late phase clinical trials”) and that are unique to specific stages of clinical development of these biological products.
The products discussed in this guidance are for therapeutic cancer vaccines, referred to as “cancer vaccines” throughout this document, intended to be administered to patients with an existing cancer for the purpose of treatment. This guidance does not apply to products intended to be administered to patients to prevent or decrease the incidence of cancer. Furthermore, this guidance does not apply to adoptive immunotherapeutic products such as T cell or NK cell products. Although clinical trials involving these products share certain overlapping features with those involving cancer vaccines, adoptive immunotherapeutic products have different mechanisms of action and unique requirements with respect to product development.

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

ida 100programme 515x64 LowRes Drug Regulators Publish Draft Clinical Guidelines for Cancer Vaccines

Turn your Business Into an Investor Magnet

How to Write a Business Plan – Free E-Course

Get the secrets that turns your project into an investment magnet, 100% of our clients raise the finance they need to take their projects to the next stage, we will share these secrets with you. – Sign up for Free

Grow your Expertise for Free

As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.

First name

E-mail address

This guideline ap
recombinant vaccines for the prevention and treatment of infectious disease, and provides guidance on quality, non-clinical and clinical aspects.
ida consultants freestrategyconsultation 515x64 Drug Regulators Publish Draft Clinical Guidelines for Cancer Vaccines

UK Drug Regulators Release New Information on Medical Devices Directive

UK Drug Regulators, MHRA, Release New Guidance for the Medical Device Directive: Information for Clinical Investigators

Full copy is available here.

In order to harmonise the process of getting approval for medical devices across Europe a common set of medical device regulations are being adopted, these are being guided by the medical devices directive. This all came into effect in 2002, and this is the latest guidance published on these guidelines.

In order to demonstrate and back up claims made for a medical device it is necessary to conduct clinical trials on Non-CE marked medical devices. In these circumstances a specifically designed clinical investigation is required. Before these trials can be conducted they need to be approved by the MHRA and an application should be filed 60 days before the trial is due to commence. An ethics committee approval is also needed for these trials, independent ethics committee opinions are not accepted by the MHRA.

These guidelines bring the medical devices process into line with the drugs guidelines in many respects. More detailed guidance on the conduct of clinical trials is also available. There is also updated guidance on vigilance systems.

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

ida 100programme 515x64 LowRes UK Drug Regulators Release New Information on Medical Devices Directive

Turn your Business Into an Investor Magnet

How to Write a Business Plan – Free E-Course

Get the secrets that turns your project into an investment magnet, 100% of our clients raise the finance they need to take their projects to the next stage, we will share these secrets with you. – Sign up for Free

Grow your Expertise for Free

As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.

First name

E-mail address

This guideline ap
recombinant vaccines for the prevention and treatment of infectious disease, and provides guidance on quality, non-clinical and clinical aspects.
ida consultants freestrategyconsultation 515x64 UK Drug Regulators Release New Information on Medical Devices Directive